No Increased Risk of Inflammatory Bowel Disease Among Secukinumab-Treated Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis: Data from 14 Phase 2 and Phase 3 Clinical Studies

被引：0
|
作者：
Deodhar, Atul A. [1 ]
Schreiber, Stefan [2 ]
Gandhi, Kunal [3 ]
Fox, Todd [4 ]
Gaillez, Corine [4 ]
Karyekar, Chetan [3 ]
机构：
[1] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[2] Christian Albrechts Univ Kiel, Kiel, Germany
[3] Novartis Pharmaceut, E Hanover, NJ USA
[4] Novartis Pharma AG, Basel, Switzerland
来源：
ARTHRITIS & RHEUMATOLOGY | 2016年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
962
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Bone Mineral Density and Serum Biomarkers of Bone Turnover in Ankylosing Spondylitis Patients Treated with Secukinumab: 2-Year Data from the Pivotal Phase 3 Study
    Braun, Juergen
    Buehring, Bjoern
    Baraliakos, Xenofon
    Gensler, Lianne S.
    Porter, Brian
    Shete, Abhijit
    Quebe-Fehling, Erhard
    Haemmerle, Sibylle
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [42] SECUKINUMAB PROVIDES CLINICAL IMPROVEMENTS IN PATIENTS WITH ACTIVE OLIGOARTICULAR PSORIATIC ARTHRITIS: RESULTS FROM A POOLED ANALYSIS OF FIVE PHASE 3 STUDIES
    Coates, Laura C.
    Ogdie, Alexis
    Gladman, Dafna D.
    Pournara, Effie
    Meng, Xiangyi
    Parikh, Bhumik
    Mease, Philip J.
    RHEUMATOLOGY, 2022, 61
  • [43] Secukinumab Provides Clinical Improvements in Patients with Active Oligoarticular Psoriatic Arthritis: Results from a Pooled Analysis of 5 Phase 3 Studies
    Ogdie, Alexis
    Gladman, Dafna
    Coates, Laura
    Pournara, Effie
    Meng, Xiangyi
    Parikh, Bhumik
    Mease, Philip
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 3812 - 3815
  • [44] SECUKINUMAB IMPROVES MINIMAL DISEASE ACTIVITY RESPONSE RATES IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: DATA FROM PHASE 3 FUTURE-2 STUDY
    Mease, P.
    Coates, L. C.
    Kirkham, B.
    McLeod, L. D.
    Mpofu, S.
    Karyekar, C.
    Gandhi, K.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (04) : 777 - 778
  • [45] Impact of psoriasis disease activity and other risk factors on serum urate levels in patients with psoriasis and psoriatic arthritis-a post-hoc analysis of pooled data from three phase 3 trials with secukinumab
    Dehlin, Mats
    Fasth, Andreas E. R.
    Reinhardt, Maximilian
    Jacobsson, Lennart T. H.
    RHEUMATOLOGY ADVANCES IN PRACTICE, 2021, 5 (01)
  • [46] SECUKINUMAB IMPROVES MINIMAL DISEASE ACTIVITY RESPONSE RATES IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: DATA FROM THE RANDOMIZED PHASE 3 STUDY, FUTURE 2
    Coates, L. C.
    Mease, P.
    Kirkham, B.
    McLeod, L. D.
    Mpofu, S.
    Karyekar, C.
    Gandhi, K.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 605 - 605
  • [47] ASAS, BASDAI AND ASDAS REMISSION IN SECUKINUMAB TREATED PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 3-YEAR RESULTS FROM A POOLED ANALYSIS OF TWO PHASE 3 STUDIES
    Baraliakos, X.
    Van den Bosch, F.
    Machado, P.
    Gensler, L.
    Bintu, S.
    Porter, B.
    Gaillez, C.
    Deodhar, A.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2018, 36 (04) : 743 - 743
  • [48] SAFETY OF GUSELKUMAB ACROSS DIVERSE PATIENT SUBGROUPS WITH PSORIATIC DISEASE: AN INTEGRATED ANALYSIS OF 11 PHASE 2/3 CLINICAL STUDIES IN PSORIASIS AND PSORIATIC ARTHRITIS
    Coates, L.
    Strober, B.
    Yu, J.
    Leibowitz, E.
    Rowland, K.
    Kollmeier, A.
    Miller, M.
    Wang, Y.
    Li, S.
    Chakravarty, S. D.
    Chan, D.
    Shawi, M.
    Yang, Y. W.
    Lebwohl, M.
    Rahman, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1134 - 1135
  • [49] Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials
    Gordon, Kenneth B.
    Langley, Richard G.
    Warren, Richard B.
    Okubo, Yukari
    Gold, Linda Stein
    Merola, Joseph F.
    Peterson, Luke
    Wixted, Krista
    Cross, Nancy
    Deherder, Delphine
    Thaci, Diamant
    JAMA DERMATOLOGY, 2022, 158 (07) : 735 - 744
  • [50] Impact of Psoriasis Disease Activity and Other Risk Factors on Serum-urate Levels in Patients with Psoriasis and Psoriatic Arthritis - A Post-hoc Analysis of Pooled Data from Three Phase 3-trials with Secukinumab
    Dehlin, Mats
    Fasth, Andreas
    Reinhardt, Maximilian
    Jacobsson, Lennart
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
12345